Safety and Efficacy of Imatinib in Chronic Myelogenous Patients Older Than 70 Years

Update Il y a 8 mois
Reference: NCT00219752

Woman and Man

  • | Country :
  • France
  • | organs :
  • -
  • | Specialty :
  • -

Extract

The aim of this phase II trial is asses the tolerability and the effectiveness of imatinib in patients with chronic myelogenous leukemia in chronic phase with age more than 70, diagnosis of cml is being performed within 1 year. Quality of life will be carefully assessed.


Inclusion criteria

  • Chronic myeloid leukemia

Links